INN-Coming: Insights on the Industry’s Latest Disclosures

Key Takeaways

• INN 134 lists NLRP3 inhibitors abdenoflast, parunoflast.
• Likely correspond to VTX2735 and VTX3232 assets.
• VTX2735 shows safety in CAPS, pericarditis trials.
• VTX3232 reduces hsCRP, impacts Parkinson's and obesity.
• LRRK2 inhibitors map to DNL151 and HT‑4253 programs.

Summary

The WHO’s INN proposed list 134, released in early 2026, reveals several late‑stage drug candidates that were previously hidden from public view. Notably, two NLRP3 inhibitors—abdenoflast and parunoflast—appear to map to Eli Lilly’s newly acquired Ventyx assets VTX2735 and VTX3232, both showing promising Phase 2 data. The list also discloses LRRK2 inhibitors liradasertib and pelerasertib, which likely correspond to Denali Therapeutics’ DNL151 (BIIB122) and Halia Therapeutics’ HT‑4253, indicating continued investment in neuro‑degenerative targets. These disclosures provide a rare glimpse into the strategic pipelines of major biotech players.

Pulse Analysis

The World Health Organization’s bi‑annual International Nonproprietary Name (INN) list serves as a low‑key intelligence source for investors and competitors alike. By publishing proposed generic names alongside molecular structures, the WHO inadvertently shines a light on late‑stage assets that companies keep under wraps. Analysts can reverse‑engineer these clues to identify pipeline trends, competitive moves, and emerging therapeutic focus areas before formal press releases appear, making the INN list a valuable early‑warning system for the pharmaceutical market.

In the latest INN 134 release, two NLRP3 inhibitors—abdenoflast and parunoflast—have been linked to Eli Lilly’s $1.2 billion acquisition of Ventyx Biosciences. The peripheral inhibitor VTX2735 has cleared a Phase 2 safety hurdle in CAPS and is now probing pericarditis, dermatology, and rheumatology indications, suggesting a broad anti‑inflammatory platform. Its CNS‑penetrant counterpart, VTX3232, demonstrated meaningful reductions in hsCRP and favorable biomarker shifts in Parkinson’s and obesity studies, positioning it as a potential dual‑indication asset that could complement existing GLP‑1 therapies. These data points reinforce Lilly’s strategy to diversify beyond traditional biologics into small‑molecule inflammation modulators.

Equally intriguing are the LRRK2 kinase inhibitors disclosed as liradasertib and pelerasertib. The former aligns with Denali Therapeutics’ DNL151/BIIB122, which remains active in a Phase 2b Parkinson’s trial despite earlier concerns about lung toxicity. The latter appears to be Halia Therapeutics’ HT‑4253, now advancing toward a Phase 2 Alzheimer’s study. Their presence on the INN list signals that the industry has mitigated prior safety worries and is re‑investing in LRRK2 as a viable neuro‑degenerative target. This resurgence could catalyze new collaborations and funding streams, reshaping the competitive landscape for both biotech innovators and large pharma partners.